Defining SOD1 ALS natural history to guide therapeutic clinical trial design

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 88, Issue 2, 2017, Pages 99-105

  Bali, Taha ^a   Self, Wade ^a   Liu, Jingxia ^a   Siddique, Teepu ^b   Wang, Leo H ^c   Bird, Thomas D ^c,d   Ratti, Elena ^e   Atassi, Nazem ^e   Boylan, Kevin B ^f   Glass, Jonathan D ^g   Maragakis, Nicholas J ^h   Caress, James B ⁱ   McCluskey, Leo F ^j   Appel, Stanley H ^k   Wymer, James P ^l   Gibson, Summer ^m   Zinman, Lorne ⁿ   Mozaffar, Tahseen ^o   Callaghan, Brian ^p   McVey, April L ^q   Jockel Balsarotti, Jennifer ^a   Allred, Peggy ^r   Fisher, Elena R ^a   Lopate, Glenn ^a   Pestronk, Alan ^a   Cudkowicz, Merit E ^e   Miller, Timothy M ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f MAYO CLINIC   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ WAKE FOREST SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k HOUSTON METHODIST HOSPITAL   (United States)

^l ALBANY MEDICAL CENTER   (United States)

^m UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁿ SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^q UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^r CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; ARTICLE; CLINICAL TRIAL (TOPIC); CODON; COHORT ANALYSIS; DISEASE COURSE; DISEASE DURATION; FEMALE; FORCED VITAL CAPACITY; GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; MUTANT; NEUROPSYCHOLOGICAL TEST; NORTH AMERICA; ONSET AGE; RESPIRATORY FUNCTION; RETROSPECTIVE STUDY; SEX RATIO; SOD1 GENE; STUDY DESIGN; SURVIVAL RATE; SURVIVAL TIME; UNIVERSITY HOSPITAL; GENETICS; METHODOLOGY; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VITAL CAPACITY;

SUPEROXIDE DISMUTASE;

ADULT; AGE OF ONSET; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; MIDDLE AGED; MUTATION; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SUPEROXIDE DISMUTASE; VITAL CAPACITY;

EID: 84973352601     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2016-313521     Document Type: Article

References (30)

1. Sorenson EJ, Stalker AP, Kurland LT, et al. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002; 59: 280-2
2. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009; 73: 1218-26
3. Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-Analysis. J Neurol Neurosurg Psychiatr 2011; 82: 623-7
4. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62
5. Robberecht W, Aguirre T, Van den Bosch L, et al. D90A heterozygosity in the SOD1 gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis. Neurology 1996; 47: 1336-9
6. Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006; 116: 2290-6
7. Miller TM, Kaspar BK, Kops GJ, et al. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol 2005; 57: 773-6
8. Winer L, Srinivasan D, Chun S, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol 2013; 70: 201-7
9. Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013; 12: 435-42
10. Crisp MJ, Mawuenyega KG, Patterson BW, et al. In vivo kinetic approach reveals slow SOD1 turnover in the CNS. J Clin Invest 2015; 125: 2772-80
11. Patel P, Kriz J, Gravel M, et al. Adeno-Associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther 2014; 22: 498-510
12. Gros-Louis F, Soucy G, Larivière R, et al. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010; 113: 1188-99
13. Riboldi G, Zanetta C, Ranieri M, et al. Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases. Mol Neurobiol 2014; 50: 721-32
14. Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005; 11: 429-33
15. Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005; 11: 423-8
16. Ray SS, Nowak RJ, Brown RH Jr, et al Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation Proc Natl Acad Sci USA 2005 102 3639-44
17. Lange DJ, Andersen PM, Remanan R, et al. Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14: 199-204
18. Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997; 41: 210-21
19. Rosen DR, Bowling AC, Patterson D, et al. A frequent ala 4 to val superoxide dismutase-1 mutation is associated with a rapidly progressive familial amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3: 981-7
20. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13-21
21. Andersen PM, Nilsson P, Keränen ML, et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain 1997; 120(Pt 10): 1723-37
22. Andersen PM, Sims KB, Xin WW, et al. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 62-73
23. Cudkowicz ME, McKenna-Yasek D, Chen C, et al. Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene. Ann Neurol 1998; 43: 703-10
24. Gellera C, Castellotti B, Riggio MC, et al. Superoxide dismutase gene mutations in Italian patients with familial and sporadic amyotrophic lateral sclerosis: identification of three novel missense mutations. Neuromuscul Disord 2001; 11: 404-10
25. Juneja T, Pericak-Vance MA, Laing NG, et al. Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu, Zn superoxide dismutase. Neurology 1997; 48: 55-7
26. Sato T, Nakanishi T, Yamamoto Y, et al. Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology 2005; 65: 1954-7
27. Stewart HG, Andersen PM, Eisen A, et al. Corticomotoneuronal dysfunction in ALS patients with different SOD1 mutations. Clin Neurophysiol 2006; 117: 1850-61
28. McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gend Med 2010; 7: 557-70
29. Czaplinski A, Yen AA, Simpson EP, et al. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing? Arch Neurol 2006; 63: 1139-43
30. Qureshi M, Schoenfeld DA, Paliwal Y, et al. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler 2009; 10: 324-31